Esophageal squamous cell carcinoma (ESCC) is a highly aggressive malignancy with poor prognosis, and understanding the ...

The addition of sintilimab to neoadjuvant chemoradiotherapy achieved a 60% pathological complete response rate vs 47.3% with ...

Transarterial infusion chemotherapy and embolization (TAICE) as a pre-operative therapy for patients with locally advanced gastric cancer (LAGC): A prospective, single-arm, pilot study.

This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does not include a full text component.

Sigvotatug vedotin is under clinical development by Pfizer and currently in Phase I for Esophageal Squamous Cell Carcinoma (ESCC). According to GlobalData, Phase I drugs for Esophageal Squamous Cell ...

Telisotuzumab adizutecan is under clinical development by AbbVie and currently in Phase I for Esophageal Squamous Cell Carcinoma (ESCC). According to GlobalData, Phase I drugs for Esophageal Squamous ...

The phase III ESCORT-NEO trial evaluated camrelizumab in combination with chemotherapy versus chemotherapy alone in the ...

Phone calls to follow up with patients with locally advanced esophageal squamous cell carcinoma while at home may reduce AEs ...

suggests that they are potential targets for cancer treatment. The mechanism of CAP heterogeneity in esophageal squamous cell carcinoma (ESCC) remains unclear, which has limited the development of ...